ClinicalTrials.gg
CompletedNCT04873934V-INCEPTIONUpdated Oct 16, 2025Results posted

Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome

A Phase 3 interventional study of Inclisiran in Acute Coronary Syndrome, sponsored by Novartis Pharmaceuticals. Completed at 88 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-10-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Acute Coronary Syndrome by Novartis — 2 open to participants now, 2 under way, 1 of them phase 3. Acute Coronary Syndrome · Novartis.

Enrollment
6th of 11
400 · median 400
Started
2021
the only one that year
Phase 3
8 of 11
1 open now
Registered
8th of 11
by date

Among the 11 studies in Acute Coronary Syndrome by Novartis, this one is the 6th largest by enrollment, is the only one that started in 2021, is one of 8 in phase 3, and was the 8th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

2 of the 11 studies in Acute Coronary Syndrome by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Acute Coronary Syndrome by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisiran in participants who have experienced a recent acute coronary syndrome (ACS) and have an increased LDL-cholesterol (≥70 mg/dL) despite being treated with a statin drug.

Read the detailed description

This was a randomized, parallel-group, open-label, multicenter, 1-year (30-day Screening Period and 330-day Treatment Period) study comparing an LDL-C management strategy including inclisiran + usual care to usual care alone. Approximately 384 participants were planned to be randomized 1:1 to aggressive LDL-C management with inclisiran + usual care (intervention arm) (3 inclisiran doses) or usual care (control arm). Usual care could have included addition of ezetimibe, bempedoic acid, PCSK9-inhibiting monoclonal antibodies, and/or commercially available inclisiran

03

Conditions studied

  • Acute Coronary Syndrome

Keywords

  • Hyperlipidemia
  • Atherosclerotic Cardiovascular Disease
  • Hypercholesterolemia
  • Lipid lowering therapies
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recent Acute Coronary Syndrome (in-patient/out-patient) within 5 weeks of screening
  • Serum LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL
  • Fasting triglycerides \<4.52 mmol/L (\<400 mg/dL) at screening
  • Calculated >20 mL/min by estimated glomerular filtration rate (eGFR)
  • Participants are required to be discharged on statin therapy, or have documented statin intolerance, as determined by the investigator, following hospitalization for an ACS. Statin intolerant participants are eligible if they had intolerable side effects on at least 2 different statins, including one at the lowest standard dose

Exclusion criteria

Exclusion Criteria:

  • (NYHA) class IIIb or IV heart failure or last known \<25%.
  • Significant cardiac arrhythmia within 3 months prior to randomization that is not controlled by medication or via ablation at the time of screening.
  • Severe concomitant non-cardiovascular disease that carries the risk of reducing to less than 2 years.
  • Treatment with other products or devices within 30 days or five half˗lives of the screening visit, whichever is longer.
  • Planned use of other investigational products or devices during the course of the study.
  • Treatment with monoclonal antibodies directed towards PCSK9 within 90 days of screening.
  • Recurrent ACS event within 2 weeks prior to randomization.
  • Coronary angiography and revascularization procedure (percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) surgery) performed within 2 weeks prior to the randomization visit or planned after randomization.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    Inclisiran with Usual Care

    Inclisiran sodium 300 mg / 1.5 ml (equivalent to 284 mg of inclisiran)

    Drug: Inclisiran

  • No intervention
    Usual Care

    Usual Care Alone

Interventions

  • Inclisiran sodium 300 mg / 1.5 ml (equivalent to 284 mg of inclisiran)

    Also known as: KJX839

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Day 330 in LDL-C

    Percent change from baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Day 330

    Time frame: Baseline and Day 330

  2. Achievement of LDL-C < 70 mg/dL at Day 330

    Percentage of participants achieving Low-Density Lipoprotein Cholesterol (LDL-C) \< 70 mg/dL at Day 330

    Time frame: Day 330

Secondary outcomes

  1. Absolute Change From Baseline in LDL-C

    Absolute change from baseline in low-density lipoprotein cholesterol (LDL-C) by visit

    Time frame: Baseline, Day 90, Day 270 and Day 330

  2. Average Percent Change From Baseline in LDL-C Levels

    Average percent change from baseline in low-density lipoprotein cholesterol (LDL-C) levels to each post-baseline visit

    Time frame: Baseline, from Day 90 to Day 330

  3. Average Absolute Change From Baseline in LDL-C Levels

    Average absolute change from baseline in low-density lipoprotein cholesterol (LDL-C) levels to each post-baseline visit

    Time frame: Baseline, From Day 90 to Day 330

  4. Achieving ≥50% Reduction From Baseline in LDL-C

    Percentage of participants achieving ≥50% reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at Day 330

    Time frame: Baseline, Day 330

  5. Achieving LDL-C < 100 mg/dL and LDL-C < 55 mg/dL

    Percentage of participants achieving low-density lipoprotein cholesterol (LDL-C) \<100 mg/dL (among the subset of participants with baseline LDL-C \>= 100 mg/dL) and LDL-C \< 55 mg/dL at Day 330

    Time frame: Day 330

  6. Percent Change in Lipids and Other Lipoproteins From Baseline to Day 330

    Percent change in apolipoprotein B, very-low-density lipoprotein (VLDL), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, lipoprotein(a) (Lp\[a\]), HDL-C and triglycerides from baseline to Day 330

    Time frame: Baseline and Day 330

  7. Absolute Change in Lipids and Other Lipoproteins From Baseline to Day 330

    Absolute change in apolipoprotein B, very-low-density lipoprotein (VLDL), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, HDL-C and triglycerides from baseline to Day 330

    Time frame: Baseline and Day 330

  8. Absolute Change in Lp[a] From Baseline to Day 330

    Absolute change in lipoprotein(a) (Lp\[a\]) from baseline to Day 330

    Time frame: Baseline and Day 330

  9. Intensity of Lipid Lowering Therapy

    Percentage of participants by intensity of lipid lowering therapy (dose decrease, increase or no change)

    Time frame: Baseline and Day 330

  10. Proportion of Days Covered

    Total number of days on either statin, ezetimibe, or PCSK9 inhibiting monoclonal antibody therapies divided by total number of study days. If a participant did not take any of the 3 medications, then the total number of days was assumed to be zero.

    Time frame: Baseline through last date of participation, up to 330 Days

  11. Discontinuation of Statin Therapy

    Percentage of participants discontinuing statin therapy. Discontinuation of statin therapy was defined as no statin use ≥ 30 days before the end-of-study visit. Participants for whom it could not be ascertained that they were on statin therapy at the end of study or who discontinued from the study early were assumed to have discontinued statin therapy.

    Time frame: Baseline and Day 330

07

Results

Posted Aug 21, 2025

Participant flow

This study was conducted at 87 study centers. Of the 201 participants randomized to inclisiran + usual care, 1 participant was randomized erroneously and did not receive inclisiran. Of the 199 participants randomized to usual care, 3 participants received commercially available inclisiran as part of their concomitant medications.

Participant flow — Overall Study
MilestoneInclisiran With Usual CareUsual Care
Started201199
Full analysis set201199
Safety set203197
Completed183173
Not completed1826
Withdrew: Adverse event01
Withdrew: Death02
Withdrew: Lost to follow-up139
Withdrew: Physician decision11
Withdrew: Protocol deviation21
Withdrew: Subject decision18
Withdrew: Withdrew consent04
Withdrew: Missing10

Outcome measures

PrimaryPercent Change From Baseline to Day 330 in LDL-C

Percent change from baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Day 330

Time frame:
Baseline and Day 330
Reported as:
Least squares mean · Percent change in LDL-C
Percent Change From Baseline to Day 330 in LDL-C
Percent change in LDL-CInclisiran With Usual CareUsual Care
Percent Change From Baseline to Day 330 in LDL-C-45.6 (-51.5 to -39.6)1.4 (-4.7 to 7.5)
Statistical analysis
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = < 0.001 · Ls mean difference: -46.9 · 97.5% CI -55.4 to -38.5
PrimaryAchievement of LDL-C < 70 mg/dL at Day 330

Percentage of participants achieving Low-Density Lipoprotein Cholesterol (LDL-C) \< 70 mg/dL at Day 330

Time frame:
Day 330
Reported as:
Number · Percentage of participants
Achievement of LDL-C < 70 mg/dL at Day 330
Percentage of participantsInclisiran With Usual CareUsual Care
Achievement of LDL-C < 70 mg/dL at Day 33066.7 (59.2 to 74.1)28.1 (21.0 to 35.3)
Statistical analysis
  • Inclisiran With Usual Care vs Usual Care · Regression, Logistic · p = < 0.001 · Odds ratio (or): 5.42 · 97.5% CI 3.29 to 8.91
SecondaryAbsolute Change From Baseline in LDL-C

Absolute change from baseline in low-density lipoprotein cholesterol (LDL-C) by visit

Time frame:
Baseline, Day 90, Day 270 and Day 330
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in LDL-C
mg/dLInclisiran With Usual CareUsual Care
Day 90-44.2 (-47.9 to -40.5)-2.2 (-6.0 to 1.6)
Day 270-34.6 (-39.2 to -30.1)-3.8 (-8.6 to 1.0)
Day 330-41.2 (-45.9 to -36.5)-3.5 (-8.3 to 1.4)
Statistical analysis
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = < 0.001 · Ls mean difference: -42.0 · 95% CI -47.3 to -36.7
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = < 0.001 · Ls mean difference: -30.8 · 95% CI -37.4 to -24.3
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = < 0.001 · Ls mean difference: -37.7 · 95% CI -44.5 to -31.0
SecondaryAverage Percent Change From Baseline in LDL-C Levels

Average percent change from baseline in low-density lipoprotein cholesterol (LDL-C) levels to each post-baseline visit

Time frame:
Baseline, from Day 90 to Day 330
Reported as:
Least squares mean · Average percent change in LDL-C
Average Percent Change From Baseline in LDL-C Levels
Average percent change in LDL-CInclisiran With Usual CareUsual Care
Average Percent Change From Baseline in LDL-C Levels-44.3 (-48.5 to -40.1)2.4 (-1.8 to 6.7)
Statistical analysis
  • Inclisiran With Usual Care vs Usual Care · ANCOVA · p = < 0.001 · Ls mean difference: -46.7 · 95% CI -52.7 to -40.8
SecondaryAverage Absolute Change From Baseline in LDL-C Levels

Average absolute change from baseline in low-density lipoprotein cholesterol (LDL-C) levels to each post-baseline visit

Time frame:
Baseline, From Day 90 to Day 330
Reported as:
Least squares mean · mg/dL
Average Absolute Change From Baseline in LDL-C Levels
mg/dLInclisiran With Usual CareUsual Care
Average Absolute Change From Baseline in LDL-C Levels-40.0 (-43.6 to -36.4)-2.7 (-6.4 to 1.0)
Statistical analysis
  • Inclisiran With Usual Care vs Usual Care · ANCOVA · p = < 0.001 · Ls mean difference: -37.3 · 95% CI -42.4 to -32.2
SecondaryAchieving ≥50% Reduction From Baseline in LDL-C

Percentage of participants achieving ≥50% reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at Day 330

Time frame:
Baseline, Day 330
Reported as:
Number · Percentage of participants
Achieving ≥50% Reduction From Baseline in LDL-C
Percentage of participantsInclisiran With Usual CareUsual Care
Achieving ≥50% Reduction From Baseline in LDL-C45.3 (38.4 to 52.2)6.5 (3.1 to 10.0)
Statistical analysis
  • Inclisiran With Usual Care vs Usual Care · Regression, Logistic · p = < 0.001 · Odds ratio (or): 11.87 · 95% CI 6.33 to 22.25
SecondaryAchieving LDL-C < 100 mg/dL and LDL-C < 55 mg/dL

Percentage of participants achieving low-density lipoprotein cholesterol (LDL-C) \<100 mg/dL (among the subset of participants with baseline LDL-C \>= 100 mg/dL) and LDL-C \< 55 mg/dL at Day 330

Time frame:
Day 330
Reported as:
Number · Percentage of participants
Achieving LDL-C < 100 mg/dL and LDL-C < 55 mg/dL
Percentage of participantsInclisiran With Usual CareUsual Care
Achieving LDL-C < 100 mg/dL75.8 (65.1 to 86.5)40.4 (27.0 to 53.7)
Achieving LDL-C < 55 mg/dL54.2 (47.3 to 61.1)13.6 (8.8 to 18.3)
Statistical analysis
  • Inclisiran With Usual Care vs Usual Care · Regression, Logistic · p = < 0.001 · Odds ratio (or): 4.38 · 95% CI 1.92 to 9.99
  • Inclisiran With Usual Care vs Usual Care · Regression, Logistic · p = < 0.001 · Odds ratio (or): 8.24 · 95% CI 4.97 to 13.65
SecondaryPercent Change in Lipids and Other Lipoproteins From Baseline to Day 330

Percent change in apolipoprotein B, very-low-density lipoprotein (VLDL), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, lipoprotein(a) (Lp\[a\]), HDL-C and triglycerides from baseline to Day 330

Time frame:
Baseline and Day 330
Reported as:
Least squares mean · Percent change
Percent Change in Lipids and Other Lipoproteins From Baseline to Day 330
Percent changeInclisiran With Usual CareUsual Care
apolipoprotein B-35.5 (-40.6 to -30.5)2.0 (-3.2 to 7.1)
VLDL Cholesterol5.7 (-1.0 to 12.3)12.1 (5.2 to 18.9)
non-HDL-Cholesterol-35.2 (-39.6 to -30.8)2.5 (-2.0 to 7.1)
Total Cholesterol-21.4 (-24.7 to -18.1)4.1 (0.6 to 7.5)
Lp[a]-10.4 (-25.9 to 5.0)5.9 (-9.7 to 21.6)
HDL-Cholesterol14.0 (10.8 to 17.3)10.6 (7.2 to 13.9)
triglycerides7.3 (0.1 to 14.4)12.3 (4.9 to 19.6)
Statistical analysis
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = < 0.001 · Ls mean difference: -37.5 · 95% CI -44.8 to -30.3
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = 0.188 · Ls mean difference: -6.4 · 95% CI -16.0 to 3.1
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = < 0.001 · Ls mean difference: -37.7 · 95% CI -44.0 to -31.4
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = < 0.001 · Ls mean difference: -25.5 · 95% CI -30.2 to -20.7
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = 0.145 · Ls mean difference: -16.4 · 95% CI -38.4 to 5.7
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = 0.141 · Ls mean difference: 3.5 · 95% CI -1.2 to 8.1
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = 0.339 · Ls mean difference: -5.0 · 95% CI -15.2 to 5.3
SecondaryAbsolute Change in Lipids and Other Lipoproteins From Baseline to Day 330

Absolute change in apolipoprotein B, very-low-density lipoprotein (VLDL), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, HDL-C and triglycerides from baseline to Day 330

Time frame:
Baseline and Day 330
Reported as:
Least squares mean · mg/dL
Absolute Change in Lipids and Other Lipoproteins From Baseline to Day 330
mg/dLInclisiran With Usual CareUsual Care
apolipoprotein B-31.0 (-34.2 to -27.8)-2.6 (-5.8 to 0.6)
VLDL Cholesterol-0.4 (-2.0 to 1.3)1.8 (0.0 to 3.5)
non-HDL-Cholesterol-41.4 (-46.5 to -36.3)-1.3 (-6.5 to 4.0)
total Cholesterol-35.2 (-40.5 to -30.0)2.5 (-2.9 to 7.9)
HDL-Cholesterol5.7 (4.3 to 7.1)3.8 (2.4 to 5.3)
triglycerides1.1 (-8.7 to 10.8)9.8 (-0.3 to 19.9)
Statistical analysis
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = < 0.001 · Ls mean difference: -28.4 · 95% CI -33.0 to -23.9
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = 0.078 · Ls mean difference: -2.1 · 95% CI -4.5 to 0.2
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = < 0.001 · Ls mean difference: -40.1 · 95% CI -47.5 to -32.8
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = < 0.001 · Ls mean difference: -37.7 · 95% CI -45.3 to -30.2
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = 0.065 · Ls mean difference: 1.9 · 95% CI -0.1 to 3.8
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = 0.222 · Ls mean difference: -8.7 · 95% CI -22.8 to 5.3
SecondaryAbsolute Change in Lp[a] From Baseline to Day 330

Absolute change in lipoprotein(a) (Lp\[a\]) from baseline to Day 330

Time frame:
Baseline and Day 330
Reported as:
Least squares mean · nmol/L
Absolute Change in Lp[a] From Baseline to Day 330
nmol/LInclisiran With Usual CareUsual Care
Absolute Change in Lp[a] From Baseline to Day 330-19.3 (-26.2 to -12.4)-5.3 (-12.2 to 1.7)
Statistical analysis
  • Inclisiran With Usual Care vs Usual Care · Mixed Models Analysis · p = 0.005 · Ls mean difference: -14.0 · 95% CI -23.8 to -4.2
SecondaryIntensity of Lipid Lowering Therapy

Percentage of participants by intensity of lipid lowering therapy (dose decrease, increase or no change)

Time frame:
Baseline and Day 330
Reported as:
Number · Percentage of participants
Intensity of Lipid Lowering Therapy
Percentage of participantsInclisiran With Usual CareUsual Care
Decrease in statin intensity9.8 (5.9 to 15.0)4.6 (2.0 to 8.9)
No change in statin intensity89.1 (83.7 to 93.2)92.5 (87.6 to 96.0)
Increase in statin intensity1.1 (0.1 to 3.9)2.9 (0.9 to 6.6)
Statistical analysis
  • Inclisiran With Usual Care vs Usual Care · proportional odds model · p = 0.031 · Odds ratio (or): 0.43 · 95% CI 0.20 to 0.93
SecondaryProportion of Days Covered

Total number of days on either statin, ezetimibe, or PCSK9 inhibiting monoclonal antibody therapies divided by total number of study days. If a participant did not take any of the 3 medications, then the total number of days was assumed to be zero.

Time frame:
Baseline through last date of participation, up to 330 Days
Reported as:
Least squares mean · Proportion of days
Proportion of Days Covered
Proportion of daysInclisiran With Usual CareUsual Care
Proportion of Days Covered0.926 (0.900 to 0.953)0.965 (0.939 to 0.992)
Statistical analysis
  • Inclisiran With Usual Care vs Usual Care · ANCOVA · p = 0.043 · Ls mean difference: -0.039 · 95% CI -0.077 to -0.001
SecondaryDiscontinuation of Statin Therapy

Percentage of participants discontinuing statin therapy. Discontinuation of statin therapy was defined as no statin use ≥ 30 days before the end-of-study visit. Participants for whom it could not be ascertained that they were on statin therapy at the end of study or who discontinued from the study early were assumed to have discontinued statin therapy.

Time frame:
Baseline and Day 330
Reported as:
Number · Percentage of participants
Discontinuation of Statin Therapy
Percentage of participantsInclisiran With Usual CareUsual Care
Discontinuation of Statin Therapy14.5 (9.2 to 19.7)18.0 (12.3 to 23.6)
Statistical analysis
  • Inclisiran With Usual Care vs Usual Care · Regression, Logistic · p = 0.346 · Odds ratio (or): 0.76 · 95% CI 0.43 to 1.35

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 330 days.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inclisiran + Usual Care0/203 (0%)32/203 (15.8%)52/203 (25.6%)
Usual Care2/197 (1%)34/197 (17.3%)35/197 (17.8%)
Most frequent serious events
Showing 10 of 80
Most frequent serious events
EventInclisiran + Usual CareUsual Care
Acute myocardial infarctionCardiac disorders8/2036/197
AnaemiaBlood and lymphatic system disorders1/2032/197
Angina pectorisCardiac disorders2/2032/197
Angina unstableCardiac disorders0/2032/197
Cardiac arrestCardiac disorders0/2032/197
Gastrointestinal haemorrhageGastrointestinal disorders0/2032/197
PneumoniaInfections and infestations0/2032/197
FallInjury, poisoning and procedural complications0/2032/197
Ischaemic strokeNervous system disorders0/2032/197
Cardiac failure acuteCardiac disorders2/2030/197
Most frequent other events
Most frequent other events
EventInclisiran + Usual CareUsual Care
Non-cardiac chest painGeneral disorders8/20310/197
Injection site painGeneral disorders10/2030/197
COVID-19Infections and infestations10/2039/197
ArthralgiaMusculoskeletal and connective tissue disorders8/2033/197
Angina pectorisCardiac disorders7/2033/197
Upper respiratory tract infectionInfections and infestations6/2036/197
Blood creatine phosphokinase increasedInvestigations5/2036/197
DizzinessNervous system disorders6/2036/197

Baseline characteristics

Age, Continuous
Age, Continuous(years)Inclisiran With Usual CareUsual CareTotal
Mean60.8 ± 10.9060.2 ± 11.6960.5 ± 11.29
Sex: Female, Male
Sex: Female, Male(Participants)Inclisiran With Usual CareUsual CareTotal
Female6353116
Male138146284
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Inclisiran With Usual CareUsual CareTotal
White166167333
Black or African American252449
Asian639
Native Hawaiian or Other Pacific Islander101
American Indian or Alaska Native101
Unknown246
Multiple011
08

Study locations

88 sites
  • Northeast Arkansas Baptist Clinic
    Jonesboro, Arkansas 72401, United States
  • Central Cardiology Medical Center
    Bakersfield, California 93308, United States
  • The Heart Group Cardiovascular Associates Inc
    Fresno, California 93720, United States
  • Mission Heritage Medical Group
    Mission Viejo, California 92691, United States
  • Northbay Clinical Research LLC
    Santa Rosa, California 95405, United States
  • Clinnova Research Solutions
    Torrance, California 90277, United States
  • Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • Interv Cardiology Med Grp
    West Hills, California 91307, United States
  • Aurora Denver Cardiology Associates
    Aurora, Colorado 80012, United States
  • Colorado Springs Cardiology
    Colorado Springs, Colorado 80907, United States
  • Colorado Heart and Vascular
    Lakewood, Colorado 80228, United States
  • Cardiology Ass of Fairfield County
    Stamford, Connecticut 06905, United States
  • Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
  • George Washington Univ Medical Ctr
    Washington D.C., District of Columbia 20037, United States
  • Nova Clinical Research LLC
    Bradenton, Florida 34209, United States
  • Teradan Clinical trials LLC
    Brandon, Florida 33511, United States
  • Clearwater Cardiovascular and Interventional Consultants
    Clearwater, Florida 33756, United States
  • Cardiology Research Associates
    Daytona Beach, Florida 32117, United States
  • Holy Cross Hospital Inc
    Fort Lauderdale, Florida 33308, United States
  • Baptist Health Research Institute
    Jacksonville, Florida 32207, United States
  • Reliant Medical Research
    Miami, Florida 33165, United States
  • Inpatient Research Clinical LLC
    Miami Lakes, Florida 33014, United States
  • Innovation Medical Group LLC
    Palmetto Bay, Florida 33157, United States
  • Cardiology Consultants
    Pensacola, Florida 32501, United States
  • Theia Clinical Research Ctrs LLC
    Tampa, Florida 33613, United States
  • Morehouse School Of Medicine
    Atlanta, Georgia 30310, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Ellipsis Group
    Atlanta, Georgia 30342, United States
  • Northside Hospital
    Atlanta, Georgia 30342, United States
  • Northwest Heart Clinical Rsrch LLC
    Arlington Heights, Illinois 60005, United States
  • AMITA Heart and Vascular Group
    Hinsdale, Illinois 60521, United States
  • Franciscan Health Services Research Center
    Indianapolis, Indiana 46237, United States
  • Cardiovascular Research Of Northwest Indiana, Llc
    Munster, Indiana 46321, United States
  • Iowa Heart Center
    Des Moines, Iowa 50314, United States
  • Midwest Heart and Vascular Spec
    Overland Park, Kansas 66211, United States
  • Tidal Health Peninsula Regional Inc
    Salisbury, Maryland 21804, United States
  • Sparrow Clincal Research Institute
    Lansing, Michigan 48912, United States
  • MidMichigan Physicians Group
    Midland, Michigan 48640, United States
  • St Marys of Ascension Research
    Saginaw, Michigan 48601, United States
  • Trinity Health Michigan Heart
    Ypsilanti, Michigan 48197, United States
  • Minneapolis Heart Institute
    Minneapolis, Minnesota 55407, United States
  • CentraCare Heart and Vascular Center
    Saint Cloud, Minnesota 56303, United States
  • Jackson Heart Clinic
    Jackson, Mississippi 39216, United States
  • Cardiology Associates of North MS
    Tupelo, Mississippi 38801, United States
  • St Louis Heart and Vascular
    St Louis, Missouri 63136, United States
  • Bryan LGH Heart Inst Intigrated Cardiology Group
    Lincoln, Nebraska 68506, United States
  • Meridian Clinical Research
    Lincoln, Nebraska 68506, United States
  • Advanced Heart Care, LLC
    Bridgewater, New Jersey 08807, United States
  • Cardiovas Assoc of Delaware Valley
    Elmer, New Jersey 08318, United States
  • Inspira Medical Cent Mullica Hill
    Mullica Hill, New Jersey 08062, United States
  • Capital Cardiology Associates
    Albany, New York 12211, United States
  • University At Buffalo
    Buffalo, New York 14203, United States
  • Bassett Medical Center
    Cooperstown, New York 13326, United States
  • Jamaica Hospital Medical Center
    Jamaica, New York 11418, United States
  • Northwell Health
    Manhasset, New York 11030, United States
  • Laurelton Heart Specialist PC
    Rosedale, New York 11422, United States
  • Cary Research Group
    Cary, North Carolina 27511, United States
  • Moses Cone Hospital-Lebauer CV Research Foundation
    Greensboro, North Carolina 27403, United States
  • Clinical Trials Of America LLC
    Lenoir, North Carolina 28645, United States
  • Pinehurst Medical Clinic
    Pinehurst, North Carolina 28374, United States
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Aultman Hospital
    Canton, Ohio 44710, United States
  • University of Toledo
    Toledo, Ohio 43614, United States
  • St John Health System
    Bartlesville, Oklahoma 74006, United States
  • Bend Memorial Clinic
    Bend, Oregon 97701, United States
  • University of Pittsburgh Medical Center HABOT
    Erie, Pennsylvania 16550, United States
  • Lancaster General Health
    Lancaster, Pennsylvania 17602, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • Guthrie Clinic
    Sayre, Pennsylvania 18840, United States
  • Monument Health Clinical Research
    Rapid City, South Dakota 57701, United States
  • Covenant Medical Group
    Knoxville, Tennessee 37916, United States
  • Baylor Scott and White Heart and Vascular Hospital
    Dallas, Texas 75226, United States
  • Vilo Research Group LLC
    Houston, Texas 77017, United States
  • Texas Heart Medical Group
    Houston, Texas 77030, United States
  • UT Physicians Memorial Hermann
    Houston, Texas 77030, United States
  • Northwest Houston Cardiology PA
    Houston, Texas 77070, United States
  • West Houston Area Clinical Trial Consultants
    Houston, Texas 77094, United States
  • The Heart Institute of East Texas
    Lufkin, Texas 75904, United States
  • CardioVoyage LLC
    McKinney, Texas 75071, United States
  • Research Group of North Texas
    Sunnyvale, Texas 75182, United States
  • Tyler Cardiovascular Consultants
    Tyler, Texas 75701, United States
  • Intermountain Medical Center
    Murray, Utah 84107, United States
  • TPMG Clinical Research
    Newport News, Virginia 23608, United States
  • York Clinical Research
    Norfolk, Virginia 23504, United States
  • Dominion Medical Associates
    Richmond, Virginia 23219, United States
  • Carilion Clinic
    Roanoke, Virginia 24013, United States
  • Selma Medical Associates
    Winchester, Virginia 22601, United States
  • MultiCare Institute for Research and Innovation
    Tacoma, Washington 98405, United States
09

References and documents

Publications

  • Knowlton KU, Navar AM, Anderson JL, Brown AS, Muhlestein JB, Kleeman K, Sarwat S, Abbas CA, Ramirez MA, Grines CL, Abo-Auda WS, Desai NR. Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial. J Am Heart Assoc. 2026 May 19;15(10):e043655. doi: 10.1161/JAHA.125.043655. Epub 2026 May 14. PubMed 42132192 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Aug 2024, 37 months.

Results were first posted in Aug 2025, 1 year after primary completion.

Of 39 phase 3 interventional studies under Acute Coronary Syndrome, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2021
First posted
May 5, 2021
StartActual
Jun 24, 2021
Primary completionActual
Aug 7, 2024
CompletionActual
Aug 7, 2024
Results first posted
Aug 21, 2025
Last update
Oct 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04873934
Responsible party
Sponsor
First posted
May 5, 2021
Start date
Jun 24, 2021
Primary completion
Aug 7, 2024
Completion
Aug 7, 2024
Results posted
Aug 21, 2025
Last update
Oct 16, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion